Serum solubleB7-H3is a prognostic marker for patients with non-muscle-invasivebladder cancer.

Takeshi Azuma,Yujiro Sato,Haruki Kume,Miyuki Azuma,Tatsukuni Ohno

doi:10.1371/journal.pone.0243379

Abstract

B7-H3 is a member of the B7 family of immune-regulatory ligands and is a costimulatory molecule promoting the T cell response in vitro. We herein investigated the clinical utility of serum soluble B7-H3 (sB7-H3) in patients with non-muscle invasive bladder cancer (NMIBC). We analyzed 555 patients in whom NMIBC was diagnosed at Tokyo Metropolitan Tama Medical Center between 2008 and 2013. We measured the serum sB7-H3 (sB7-H3) level using the enzyme-linked immunosorbent assay (ELISA) and evaluated the utility of sB7-H3 as a prognostic biomarker for NMIBC. We used the Cox proportional hazards regression model to assess recurrence-free survival (RFS) and progression-free survival (PFS) with the sB7-H3 level. We detected high levels of sB7-H3 in the sera of 47% of patients with NMIBC versus only 8% in healthy donors. The increase of sB7-H3 was significantly associated with poor RFS and PFS. Multivariate analysis showed that elevated sB7-H3 was an independent prognostic factor of RFS and PFS. According to the European Organization for Research and Treatment of Cancer (EORTC), in intermediate-low and intermediate-high risk groups, the presence of sB7-H3 significantly determined the rate of recurrence and progression. Our data suggested that evaluating serum sB7-H3 expression is a useful tool for predicting the prognosis of patients with NMIBC.

Highlights

Transurethral resection of bladder tumor (TURBT) is usually performed to resect non-muscle invasive bladder cancer (NMIBC) completely [1, 2]
The increase of soluble B7-H3 (sB7-H3) was significantly associated with poor recurrence-free survival (RFS) and progression-free survival (PFS)
Multivariate analysis showed that elevated sB7-H3 was an independent prognostic factor of RFS and PFS

Summary

Introduction

Transurethral resection of bladder tumor (TURBT) is usually performed to resect non-muscle invasive bladder cancer (NMIBC) completely [1, 2]. Clinical, prognostic features are associated with recurrence and progression Based on these features, the European Association of Urology (EAU) recommends the European Organization for Research and Treatment of Cancer (EORTC) guidelines’ classification of patients with NMIBC into four groups to predict recurrence and progression [5, 6]. The European Association of Urology (EAU) recommends the European Organization for Research and Treatment of Cancer (EORTC) guidelines’ classification of patients with NMIBC into four groups to predict recurrence and progression [5, 6] This classification system is helpful for predicting the recurrence and progression of NMIBC, it fails to take into consideration a number of newly reported factors. We investigated the clinical utility of serum soluble B7-H3 (sB7-H3) in patients with non-muscle invasive bladder cancer (NMIBC)

Methods

Results

Conclusion